Lipexal (Simvastatin)

Simvastatin is converted in the body to its active form, which competitively inhibits the enzyme HMG‑CoA reductase. This enzyme catalyzes a key step in hepatic cholesterol synthesis. By blocking it, intracellular cholesterol falls, prompting the liver to increase LDL‑receptor expression and clear more LDL‑cholesterol from the bloodstream.

The appropriate dose of Lipexal is individualized by the prescribing clinician based on the patient’s baseline lipid profile, cardiovascular risk, age, renal and hepatic function, and any concomitant medications. No fixed regimen is provided here; the prescriber sets the dosage according to clinical guidelines.

The safety of simvastatin in pregnancy and lactation has not been established, and the product is generally contraindicated for these populations. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative lipid‑lowering strategies with their healthcare provider.

To place an order, submit an enquiry on the Lipexal product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lipexal (simvastatin) belongs to the statin class, which also includes agents such as atorvastatin and rosuvastatin. Compared with some higher‑potency statins, simvastatin may require higher doses to achieve similar LDL‑C reductions, but it is often well‑tolerated and cost‑effective for many patients.

Lipexal tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Lipexal is taken orally, usually once daily in the evening, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

The most serious adverse reactions include rhabdomyolysis—a severe muscle breakdown that can lead to kidney failure—and significant liver injury manifested by marked elevations in transaminases or jaundice. Patients should promptly report unexplained muscle pain, weakness, or dark urine, as well as signs of liver dysfunction such as yellowing of the skin or eyes.

Lipexal is contraindicated in individuals with active liver disease, unexplained persistent elevations of hepatic enzymes, known hypersensitivity to simvastatin or any excipients, and in pregnant or nursing women. Caution is also advised for patients taking strong CYP3A4 inhibitors or those with severe renal impairment.